Subgroup analyses showed that using whole flaxseed in doses ≥30 g d-1 , longer-term interventions ( ≥12 weeks ) and studies including participants with higher BMI ( ≥ 27 kg m-2 ) had positive effects on body composition  .
Whole flaxseed is a good choice for weight management particularly for weight reduction in overweight and obese participants
Flaxseed consumption may be inversely associated with obesity ; however , findings of available r and omized controlled trials ( RCTs ) are conflicting .
The present study aim ed to systematic ally review and analyse RCTs assessing the effects of flaxseed consumption on body weight and body composition .
A randomized trial of the effects of ezetimibe on the absorption of omega-3 fatty acids in cardiac disease patients: A pilot study.
BACKGROUND AND AIMS Elevated levels of circulating omega-3 polyunsaturated fatty acids like alpha linolenic acid ( ALA ) may be beneficial for cardiovascular health . Circulating ALA concentrations are elevated dramatically by a cholesterol supplemented diet which increases ALA bioavailability through enhanced micelle formation in the intestines . Conversely , it is possible that drugs which inhibit cholesterol metabolism in the intestine may also inhibit fatty acid absorption . The purpose of this study is to determine if a cholesterol absorption inhibitor , ezetimibe , will decrease circulating levels of ALA . METHODS AND RESULTS Cardiac patients ( n = 34 ) between 44 and 80 years old , requiring statin therapy to regulate blood cholesterol levels , were r and omly assigned to one of four groups for a 6 week trial : 1 ) placebo ; 2 ) ezetimibe therapy ; 3 ) a supplement of flaxseed oil ( containing 1.0 g ALA in 2.0 g of flaxseed oil ) ; or 4 ) ezetimibe and flaxseed oil supplementation . Ingestion of flaxseed oil result ed in a significant increase in circulating ALA levels ( 6 ug/dl ) in patients who were not given ezetimibe . However , in the presence of ezetimibe , circulating ALA levels did not increase significantly even in the presence of flax oil supplementation ( a decrease of 4 ug/dl ) . There were no significant differences amongst the groups in terms of circulating total cholesterol , LDL , HDL , triglyceride levels in the blood . CONCLUSION Ezetimibe therapy inhibited the absorption of omega-3 fatty acids . Patients receiving ezetimibe therapy may not receive the expected cardiovascular benefits from dietary supplementation with omega-3 fatty acids . CLINICAL TRIAL REGISTRATION NCT00955227
Subgroup analyses showed that using whole flaxseed in doses ≥30 g d-1 , longer-term interventions ( ≥12 weeks ) and studies including participants with higher BMI ( ≥ 27 kg m-2 ) had positive effects on body composition  .
Whole flaxseed is a good choice for weight management particularly for weight reduction in overweight and obese participants
Flaxseed consumption may be inversely associated with obesity ; however , findings of available r and omized controlled trials ( RCTs ) are conflicting .
The present study aim ed to systematic ally review and analyse RCTs assessing the effects of flaxseed consumption on body weight and body composition .